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Introduction: Several cases of long bone giant cell tumor have been reported in the literature. We report the case
of a patient with a giant cell tumor in the distal ulna. This is very unusual, with a reported incidence of 0.45 to 6%.
Case presentation: A 17-year-old Colombian man presented with a painful swelling of the left wrist. After
performing an instrumental examination, a diagnosis of distal ulna giant cell tumor was made. The tumor was
treated with an intralesional curettage, phenol application and bone grafting.
Conclusions: This tumor may have a good prognosis if it is diagnosed early and radically treated. It is important to
be aware of atypical cancer localizations in order to perform a proper diagnosis.
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Bone giant cell tumor (GCT) is a rare, generally benign
and locally aggressive tumor. It represents approximately
3% to 5% of all primary bone cancers. It generally occurs
in adults between the ages of 20 and 40 years. GCT of
bone is very rarely seen in children or in adults older than
65 years of age. GCT tumors occur in approximately one
person per million per year. Usually, the tumor site is at
the long bone meta-epiphysis, especially the distal radius
and femur, proximal humerus and tibia. The ulna distal
extremity is an unusual site (0.45% to 3.2%) for a primary
bone GCT. We report the case of a distal ulna GCT diag-
nosed in a 17-year-old man. It was treated with intrale-
sional curettage, adjuvant therapy with 5% phenol and a
synthetic bone graft reconstruction.Case presentation
A radiographic examination of the left wrist was per-
formed in a 17-year-old Colombian man as a result of a
direct incidental trauma. No fracture was seen, but an
osteolytic area was found in the ulnar meta-epiphysis.
The initial diagnosis was ‘juvenile bone cyst’. The patient
presented with a painful swelling at the wrist dorsal
ulnar side, about 2.5 cm, in the absence of any epidermal
dyschromias. The skin was elastic and smooth. Wrist
examination showed a range of motion (ROM) of 45 ° of* Correspondence: v.salini@unich.it
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reproduction in any medium, provided the orextension, 70 ° of flexion, 15 ° of radial deviation and
10 ° of ulnar deviation; pronation, supination and cir-
cumduction were painful. Contralateral wrist ROM was
normal. The diagnosis of ‘juvenile bone cyst’ did not
seem right and a second radiographic examination was
performed. At this time, a multilocular osteolytic area
inducing an expansion of the distal ulna was seen. A
cortical bone interruption was also visible. Although the
patient had been the victim of a trauma, this was a poor
prognostic sign. Therefore an Magnetic resonance im-
aging examination was performed. It showed a hypoin-
tense signal in the T1 sequences and a hyperintense
signal in the short TI inversion recovery (STIR)
sequences, characterized by enhancement after contrast
administration, due to the presence of newly formed tis-
sue (Figure 1).
After an incisional biopsy, the diagnosis of GCT was
finally made, although it was in an atypical site.
The lesion was classified as a grade II with fracture
(Figure 1), according to the Campanacci Classification
and as a stage II according to the Enneking Classifica-
tion for benign bone tumors (Figure 2).
Subsequently, the patient was surgically treated with
intralesional curettage, adjuvant therapy with 5% phenol
and a synthetic bone graft reconstruction.
A cortical bone rawplug was removed through a skin
incision at the dorsomedial side of the deformity. Acces-
sing the cystic cavity revealed a gelatinous ‘chocolate
brown’ material, with many areas of darker color.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 X-rays and magnetic resonance imaging with and without contrast.
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(Figure 3), and then 5% phenol was applied in three
cycles (Figure 4), with subsequent neutralization by
hydrogen peroxide.
Then, using synthetic cancellous bone substitutes, a
bone defect fill was performed (Figure 5) and the bone
rawplug was synthesized using a cannulated screw
(Figure 6, Figure 7).
A clinical and radiographic follow-up was performed
one, three, six, 12, 24 and 48 months post-operatively to
evaluate the bone consolidation. Chest radiographs were
performed every six months. Within the first post-
operative month, the patient completely recovered the
wrist ROM. After 3 years, there have been no signs of
recurrence.Discussion
The bone GCT was first described in 1818 by Cooper
and Travers. Its local aggression has been highlighted by
Nelaton and its malignant potential by Virchow.
It is a rare tumor, essentially benign, but it may behave
unexpectedly, regardless of the results of radiological or
histological examinations.
It is usually located in the long bone meta-epiphysis
and it frequently involves the subchondral bone without
involvement of the articular surface; however, larger
tumors may extend into the metaphysis and, more
rarely, into the diaphysis. Proximal tibia, humerus, distal
femur and radius are typical sites.
GCT represents about 3% to 5% of all bone tumors
and 21% of benign bone tumors [1,2].
Figure 4 Curettage, adjuvant administration of 5% phenol and
subsequent neutralization with hydrogen peroxide.
Figure 2 Mononuclear stromal cells associated with
osteoclast-like multinucleated giant cells evenly distributed.
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fourth decade of life.
The distal epiphysis of the ulna is an unusual place for
a primary bone GCT; in fact, this occurs in only 0.45%
to 3.2% of all primary bone GCT’s [3].
In the past, these tumors were treated with amputa-
tion or large resections and ulterior reconstructions.
Currently, surgical treatments are:
 Intralesional curettage
 Curettage and bone grafting
 Cryotherapy of the cavity after curettage
 Application of phenol after curettage
 Radiation
 Insertion of methyl methacrylate cement in the
cavity after curettage
 Resection followed by allograftFigure 3 Emptying of giant cell tumor. En-bloc resection with or without reconstruction or
stabilization of the ulna and prosthetic
reconstruction
 Embolization of the feeding vessels
The variables related to the tumor, such as size, location,
biological activity, cortical bone destruction or pathologic
fracture evidence, determine the treatment [4].
Although an en-bloc resection radically assaults the
tumor, significantly reducing the risk of recurrence, func-
tional outcome is very bad. A simple curettage provides an
excellent functional outcome, but with a higher recurrence
rate of approximately 40% [1-5] if compared with the
patients who received adjuvant therapy (45% versus 18%).
Therefore, various adjuvant therapies have been asso-
ciated with the curettage: phenol, cryotherapy [6-8], cement
or polymethyl methacrylate (PMMA) used intraoperatively.Figure 5 Reconstruction with synthetic bone.
Figure 6 Osteosynthesis and stabilization with a cannulated
screw.
Figure 7 a-b: Post-operative radiology.
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ment is used, and approximately 2.3% after cryosurgery
[6,7].
However, it needs to be mentioned that a multicenter
study of the Canadian Sarcoma Group [9] reported an
overall recurrence rate of 17% and claimed that the fill-
ing material or the type of adjuvant would not have an
absolute impact on recurrence.
Furthermore, some studies show that the use of an ad-
juvant would not be necessary in some cases, such as
intraosseous GCT [10].
According to Schajowicz [11], curettage alone is an in-
adequate oncological procedure, but when it is com-
bined with an adjuvant therapy, it globally provides a
better result with respect to one-block excision, espe-
cially in terms of functionality.
Therefore, the correct treatment must achieve a bal-
ance between oncological radicality and the restoration
of skeletal segment functionality [12-14].
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shown to be effective in many cases [15]. In this study it
is used with phenol as an adjuvant, because it is capable
of causing protein and DNA coagulation, inducing cell
necrosis.
In the present case intralesional curettage was possible
because the tumor was a grade II and the reconstruction
was carried out with synthetic cancellous bone, due to
the young age of the patient.
Conclusions
Neoformation bone diagnosis is difficult and requires a
great deal of experience, especially in young patients.
Osteolytic lesions incidentally found at a long bone
epiphysis, can be misinterpreted. This tumor may have a
good prognosis if treated early and radically. It is import-
ant to know atypical cancer locations in order to per-
form a proper diagnosis.
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